The outcome of molecular-cytogenetic subgroups in pediatric T-cell acute lymphoblastic leukemia: a retrospective study of patients treated according to DCOG or COALL protocols.
Standard
The outcome of molecular-cytogenetic subgroups in pediatric T-cell acute lymphoblastic leukemia: a retrospective study of patients treated according to DCOG or COALL protocols. / Grotel, van; Martine, [Unbekannt]; Meijerink, [Unbekannt]; Jules, P P; Beverloo, [Unbekannt]; Berna, H; Langerak, [Unbekannt]; Anton, W; Buys-Gladdines, [Unbekannt]; Jessica, G C A M; Schneider, [Unbekannt]; Pauline, [Unbekannt]; Poulsen, [Unbekannt]; Tim, S; Den, Boer; Monique, L; Horstmann, Martin; Martin, [Unbekannt]; Kamps, [Unbekannt]; Willem, A; Veerman, [Unbekannt]; Anjo, J P; Wering, van; Elisabeth, R; Noesel, van; Max, M; Pieters, [Unbekannt]; Rob, [Unbekannt].
In: HAEMATOLOGICA, Vol. 91, No. 9, 9, 01.09.2006, p. 1212-1221.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The outcome of molecular-cytogenetic subgroups in pediatric T-cell acute lymphoblastic leukemia: a retrospective study of patients treated according to DCOG or COALL protocols.
AU - Grotel, van
AU - Martine, [Unbekannt]
AU - Meijerink, [Unbekannt]
AU - Jules, P P
AU - Beverloo, [Unbekannt]
AU - Berna, H
AU - Langerak, [Unbekannt]
AU - Anton, W
AU - Buys-Gladdines, [Unbekannt]
AU - Jessica, G C A M
AU - Schneider, [Unbekannt]
AU - Pauline, [Unbekannt]
AU - Poulsen, [Unbekannt]
AU - Tim, S
AU - Den, Boer
AU - Monique, L
AU - Horstmann, Martin
AU - Martin, [Unbekannt]
AU - Kamps, [Unbekannt]
AU - Willem, A
AU - Veerman, [Unbekannt]
AU - Anjo, J P
AU - Wering, van
AU - Elisabeth, R
AU - Noesel, van
AU - Max, M
AU - Pieters, [Unbekannt]
AU - Rob, [Unbekannt]
PY - 2006/9/1
Y1 - 2006/9/1
N2 - BACKGROUND AND OBJECTIVES: Subgroups of T-cell acute lymphoblastic leukemia (T-ALL), defined according to recurrent cytogenetic aberrations, may have different prognoses. The aim of this study was to determine the prognostic relevance of molecular-cytogenetic abnormalities in pediatric patients using quantitative real-time polymerase chain reaction and fluorescence in situ hybridization. DESIGN AND METHODS: The patients were assigned to TAL1, HOX11/TLX1, HOX11L2/TLX3, or CALM-AF10 subgroups. The cytogenetic subgroups were characterized in relation to immunophenotype and the expression of aberrantly expressed transcription factors. RESULTS: In our cohort study, CALM-AF10 was associated with an immature immunophenotype and poor outcome (p=0.005). HOX11L2 was associated with both immunophenotypically immature cases as well as cases committed to the gammadelta-lineage. HOX11L2 was significantly associated with poor outcome (p=0.01), independently of the expression of CD1 or the presence of NOTCH1 mutations. TAL1 abnormalities were associated with alphabeta-lineage commitment, and tended to be associated with a good outcome. Cells in HOX11 cases resembled early CD1-positive cortical thymocytes without expression of Cytbeta and TCR molecules. In relation to the expression of early T-cell transcription factors, high TAL1 levels were found in immunophenotypically-advanced cases, whereas high LYL1 levels were found in immature subgroups. INTERPRETATION AND CONCLUSIONS: The reported outcomes for HOX11L2-rearranged T-ALL cases are conflicting; the prognostic impact may depend on the therapy given. In our cohort, this cytogenetic aberration was associated with a poor outcome. Our data on CALM-AF10 rearranged T-ALL, albeit based on only three patients, suggest that this type of leukemia is associated with a poor outcome.
AB - BACKGROUND AND OBJECTIVES: Subgroups of T-cell acute lymphoblastic leukemia (T-ALL), defined according to recurrent cytogenetic aberrations, may have different prognoses. The aim of this study was to determine the prognostic relevance of molecular-cytogenetic abnormalities in pediatric patients using quantitative real-time polymerase chain reaction and fluorescence in situ hybridization. DESIGN AND METHODS: The patients were assigned to TAL1, HOX11/TLX1, HOX11L2/TLX3, or CALM-AF10 subgroups. The cytogenetic subgroups were characterized in relation to immunophenotype and the expression of aberrantly expressed transcription factors. RESULTS: In our cohort study, CALM-AF10 was associated with an immature immunophenotype and poor outcome (p=0.005). HOX11L2 was associated with both immunophenotypically immature cases as well as cases committed to the gammadelta-lineage. HOX11L2 was significantly associated with poor outcome (p=0.01), independently of the expression of CD1 or the presence of NOTCH1 mutations. TAL1 abnormalities were associated with alphabeta-lineage commitment, and tended to be associated with a good outcome. Cells in HOX11 cases resembled early CD1-positive cortical thymocytes without expression of Cytbeta and TCR molecules. In relation to the expression of early T-cell transcription factors, high TAL1 levels were found in immunophenotypically-advanced cases, whereas high LYL1 levels were found in immature subgroups. INTERPRETATION AND CONCLUSIONS: The reported outcomes for HOX11L2-rearranged T-ALL cases are conflicting; the prognostic impact may depend on the therapy given. In our cohort, this cytogenetic aberration was associated with a poor outcome. Our data on CALM-AF10 rearranged T-ALL, albeit based on only three patients, suggest that this type of leukemia is associated with a poor outcome.
KW - Adolescent
KW - Antineoplastic Combined Chemotherapy Protocols
KW - Child
KW - Child, Preschool
KW - Chromosome Aberrations
KW - Cytogenetic Analysis
KW - Female
KW - Humans
KW - Leukemia-Lymphoma, Adult T-Cell
KW - Male
KW - Oncogene Proteins, Fusion
KW - Prognosis
KW - Retrospective Studies
KW - Treatment Outcome
M3 - SCORING: Journal article
C2 - 16956820
VL - 91
SP - 1212
EP - 1221
JO - HAEMATOLOGICA
JF - HAEMATOLOGICA
SN - 0390-6078
IS - 9
M1 - 9
ER -
